1. Home
  2. GPRE vs AKBA Comparison

GPRE vs AKBA Comparison

Compare GPRE & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Green Plains Inc.

GPRE

Green Plains Inc.

HOLD

Current Price

$10.25

Market Cap

631.4M

Sector

Industrials

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.58

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPRE
AKBA
Founded
2004
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
631.4M
729.1M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
GPRE
AKBA
Price
$10.25
$1.58
Analyst Decision
Hold
Strong Buy
Analyst Count
8
6
Target Price
$8.69
$6.25
AVG Volume (30 Days)
1.7M
5.0M
Earning Date
11-05-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,246,853,000.00
$225,071,000.00
Revenue This Year
N/A
$52.38
Revenue Next Year
N/A
$22.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.49
52 Week Low
$3.14
$1.45
52 Week High
$12.31
$4.08

Technical Indicators

Market Signals
Indicator
GPRE
AKBA
Relative Strength Index (RSI) 51.82 36.99
Support Level $9.53 $1.45
Resistance Level $10.43 $1.63
Average True Range (ATR) 0.55 0.10
MACD 0.03 0.03
Stochastic Oscillator 73.61 39.74

Price Performance

Historical Comparison
GPRE
AKBA

About GPRE Green Plains Inc.

Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: